Overview

Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This study will be an open-label, randomised, four-period, four-treatment, crossover study in healthy male and female of non-childbearing potential subjects, performed at a single study centre. The objective of the study is to assess the bioavailability of ticagrelor orodispersible (OD) tablets when administered with water, without water and suspended in water to be administered through nasogastric tubes, compared to ticagrelor immediate-release (IR) tablets
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Ticagrelor